Syn-Ake
Also known as: Dipeptide Diaminobutyroyl Benzylamide Diacetate, Snake venom peptide mimic, Waglerin-1 analog
Overview
Syn-Ake is a synthetic tripeptide analog of Waglerin-1, the main neurotoxic peptide from the venom of the temple pit viper Tropidolaemus wagleri. Like its natural template, Syn-Ake antagonizes muscular nicotinic acetylcholine receptors (nAChRs) in a reversible, competitive manner, reducing the intensity and frequency of facial muscle contractions without causing true neurotoxicity. Applied topically, it is marketed as a 'snake venom in a cream' cosmeceutical for smoothing expression lines, and clinical studies support improvements in wrinkle appearance.
Mechanism of Action
Syn-Ake binds the muscular nicotinic acetylcholine receptor (nAChR, α1β1γδ subunit composition) at the acetylcholine binding site, acting as a competitive reversible antagonist. This reduces postsynaptic membrane depolarization in response to acetylcholine release, attenuating muscle contraction strength at neuromuscular junctions in facial skin. The effect is dose-dependent, reversible, and localized to the dermis upon topical application, unlike systemic nAChR antagonists.
Potential Benefits
- Reduction of wrinkle depth in expression lines
- Reversible muscle relaxation at neuromuscular junctions
- Clinical studies show improvement in glabellar and periorbital lines
- Complementary mechanism to Argireline (pre/post-synaptic combination)
- Good cosmeceutical safety profile
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 2% SYN-AKE serum 1x daily |
| Intermediate | 4% SYN-AKE serum 2x daily |
| Advanced | 4% SYN-AKE combined with Argireline and Matrixyl |
| Cycle Duration | Continuous cosmetic use |
Dipeptide diaminobutyroyl benzylamide diacetate. Mimics Waglerin-1 snake venom — nAChR antagonist.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Topical (serum/cream) Limited penetration — superficial action
Apply to expression lines.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Syn-Ake:
'Topical Botox' Stack
Combined neuromuscular-modulating and collagen-stimulating cosmetic peptides.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store at room temperature, away from light and heat |
|---|
Topical/cosmetic peptide — comes pre-formulated. No reconstitution needed.
Need exact syringe measurements?
Amino Acid Sequence
Dipeptide Diaminobutyroyl Benzylamide Diacetate (non-standard residues)
Side Effects & Safety
- Well-tolerated topically
- Rare skin sensitization
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store cream/serum at room temperature away from direct sunlight and heat. Refrigeration optional to extend shelf life. |
Synergistic Compounds
The following compounds have been studied alongside Syn-Ake for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.